Key Takeaway
AEBI looks like a stock insiders are telling you not to overthink. The headline objection is obvious — trailing earnings are weak, with a 110.55x P/E and just a 0.5% net margin — but that backward-looking bear case falls apart when you look at the order book and management’s 2026 outlook. Q1 order intake rose 9%, backlog climbed 23% to $1.3 billion, and the company reaffirmed full-year guidance for $1.95 billion to $2.15 billion in sales and $175 million to $195 million of adjusted EBITDA. When five insiders buy in a cluster after that print, the message is simple: they see conversion ahead, not deterioration.
AEBI’s 23% year-over-year backlog growth to $1.3 billion is the number the bearish narrative is missing.
Eight recent insider buys totaling $456,398 with zero sells signal unusually broad internal conviction.
The stock looks expensive on trailing P/E at 110.55x, but much cheaper on 0.51x sales and 0.93x book.
Management reaffirmed 2026 guidance for $1.95 billion to $2.15 billion in sales and $175 million to $195 million of adjusted EBITDA.
The real risk is not demand but earnings conversion, because net margin is still only 0.5%.
The case for our take on AEBI
The cleanest bull point is demand visibility. In Q1 2026, Aebi Schmidt posted net sales of $455.6 million, but the more important figure was the $1.3 billion backlog, up 23% year over year, alongside 9% order intake growth. That matters because this is not a story built on hope or multiple expansion alone; it is a story built on booked business. Management then reaffirmed full-year 2026 guidance of $1.95 billion to $2.15 billion in sales and $175 million to $195 million of adjusted EBITDA, with leverage at or below 2.0x, which tells you the quarter did not shake confidence internally.
